BNP Paribas Purchases Shares of 330 GE HealthCare Technologies Inc. (NASDAQ:GEHC)

BNP Paribas acquired a new position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 330 shares of the company’s stock, valued at approximately $30,000.

A number of other hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of GE HealthCare Technologies by 14.7% during the third quarter. Vanguard Group Inc. now owns 44,531,402 shares of the company’s stock worth $3,029,917,000 after acquiring an additional 5,693,244 shares during the last quarter. Norges Bank acquired a new position in GE HealthCare Technologies in the fourth quarter valued at $229,052,000. Capital Research Global Investors raised its holdings in shares of GE HealthCare Technologies by 2.8% in the fourth quarter. Capital Research Global Investors now owns 51,344,719 shares of the company’s stock valued at $3,969,975,000 after buying an additional 1,401,566 shares during the last quarter. Perpetual Ltd acquired a new stake in shares of GE HealthCare Technologies during the first quarter worth about $96,135,000. Finally, Stonegate Investment Group LLC grew its holdings in shares of GE HealthCare Technologies by 3,555.0% during the fourth quarter. Stonegate Investment Group LLC now owns 654,391 shares of the company’s stock worth $50,598,000 after buying an additional 636,487 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

GE HealthCare Technologies Stock Down 0.9 %

GEHC stock opened at $76.35 on Tuesday. GE HealthCare Technologies Inc. has a one year low of $62.35 and a one year high of $94.50. The stock has a market capitalization of $34.85 billion, a P/E ratio of 22.32, a PEG ratio of 2.77 and a beta of 1.20. The company has a 50 day moving average price of $78.69 and a two-hundred day moving average price of $81.90. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.83 and a current ratio of 1.06.

GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) last released its earnings results on Tuesday, April 30th. The company reported $0.90 EPS for the quarter, meeting the consensus estimate of $0.90. The firm had revenue of $4.65 billion during the quarter, compared to analyst estimates of $4.80 billion. GE HealthCare Technologies had a return on equity of 25.32% and a net margin of 8.05%. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.85 earnings per share. As a group, sell-side analysts expect that GE HealthCare Technologies Inc. will post 4.27 EPS for the current year.

GE HealthCare Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 15th. Stockholders of record on Friday, July 19th will be paid a dividend of $0.03 per share. The ex-dividend date of this dividend is Friday, July 19th. This represents a $0.12 annualized dividend and a dividend yield of 0.16%. GE HealthCare Technologies’s dividend payout ratio is presently 3.51%.

Insider Transactions at GE HealthCare Technologies

In other GE HealthCare Technologies news, CEO Jan Makela sold 66,955 shares of the business’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $81.54, for a total transaction of $5,459,510.70. Following the completion of the sale, the chief executive officer now owns 63,348 shares of the company’s stock, valued at $5,165,395.92. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CTO Taha Kass-Hout sold 3,300 shares of the stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $78.70, for a total value of $259,710.00. Following the completion of the sale, the chief technology officer now owns 67,300 shares of the company’s stock, valued at $5,296,510. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jan Makela sold 66,955 shares of GE HealthCare Technologies stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $81.54, for a total transaction of $5,459,510.70. Following the transaction, the chief executive officer now owns 63,348 shares in the company, valued at approximately $5,165,395.92. The disclosure for this sale can be found here. Insiders sold a total of 90,482 shares of company stock worth $7,369,137 in the last ninety days. Insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on GEHC shares. Citigroup lifted their target price on GE HealthCare Technologies from $88.00 to $103.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Bank of America dropped their price objective on shares of GE HealthCare Technologies from $94.00 to $86.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 1st. Argus raised their target price on shares of GE HealthCare Technologies from $80.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Evercore ISI lifted their target price on shares of GE HealthCare Technologies from $93.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Finally, Mizuho cut their price target on shares of GE HealthCare Technologies from $110.00 to $105.00 and set a “buy” rating for the company in a report on Wednesday, May 1st. Five analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $94.09.

Read Our Latest Research Report on GE HealthCare Technologies

GE HealthCare Technologies Company Profile

(Free Report)

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.

See Also

Receive News & Ratings for GE HealthCare Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GE HealthCare Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.